Skip to main content

Table 1 Clinical and pathological characteristics of patients in the RP-TMA.

From: Ebp1 expression in benign and malignant prostate

Number of patients selected 62
Age median (min-max) 62 (49 – 70)
Pathological Stage  
Stage 2 34 (54.8%)
Stage 3 29(46.8%)
Invasion  
Extracapsular 19(30.6%)
Lymph node 9(14.5%)
Perineural 9(14.5%)
Positive surgical margins 32(51.6%)
Prostatitis 1 (1.6%)
Gleason score  
Gleason 4 8 (12.9%)
Gleason 5 14 (22.6%)
Gleason 6 13 (21.0%)
Gleason 7 17(27.4%)
Gleason 8–9 10(16.1%)
Pre-operative PSA  
<10 ng 35 (56.5%)
> 10 ng 25 (40.3%)
not available 2 (3,2%)
PSA relapse 35 (56.5%)
Hormone refractory disease 5(8.1%)
Overall survival 54(87.1%)
  1. Clinico-pathological parameters of the 62 patients selected for the construction of the RP-TMA.